METHODS: Retrospective chart review was conducted on patients aged 18 or older who underwent EBUS-TBNA between January 1, 2009 and December 31, 2014 at our institution. Patients were excluded from analysis if taking anti-platelet medications other than clopidogrel and/or aspirin, if using therapeutic anticoagulation, if had history of bleeding or clotting disorder, active disseminated intravascular coagulation, or platelet count <80,000. Adverse bleeding events were defined as any one of the following: immediate bleeding requiring procedural interruption and/or topical intervention, red blood cell transfusion requirement within 24 hours of procedure, hemoglobin drop ≥ 2 grams, or readmission within 48 hours of procedure for hemoptysis or anemia. Data included demographics, comorbidities, and pre/post procedure CBC. Data was analyzed via one-way ANOVA and chi-square tests.